-
2024-519445-29-00
1
2025-10-02
Solid Tumors
-
2024-514030-20-00
4
2025-08-29
colorectal cancer
-
2022-502983-19-00
4
2025-07-31
High-Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cance
-
2024-519322-20-00
5
2025-07-21
metastatic colorectal cancer
-
2024-515884-69-00
5
2025-07-16
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
-
2024-519262-42-00
4
2025-07-15
NSCLC non-small cell lung cancer
-
2024-514947-27-00
9
2025-06-18
Advance solid tumors
-
2024-515764-31-00
10
2025-06-13
Non-small cell lung cancer
-
2023-506206-38-00
4
2025-04-09
Diffuse Large B-cells non-Hodgkin Lymphoma
-
2024-515214-41-00
5
2025-03-27
advanced pancreatic cancer
-
2024-515445-42-00
5
2025-03-24
Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast
-
2024-519514-31-00
4
2025-01-31
metastatic triple-negative PD-L1 positive breast cancer
-
2024-511945-20-00
4
2025-01-24
patients affected by small cell lung cancer (SCLC)
-
2024-516841-38-00
4
2025-01-09
recurrent ovarian cancer wild type for germline and somatic BRCA 1 and
-
2024-516842-21-00
5
2025-01-09
Recurrent ovarian cancer
-
2024-519481-44-00
4
2025-01-08
colorectal metastatic cancer
-
2024-513163-57-00
4
2024-12-20
Breast Cancer
-
2024-513860-25-00
9
2024-12-10
Ovarian Neoplasms
-
2024-516839-27-00
4
2024-12-09
BRCA wild-type advanced ovarian, fallopian tube and primitive peritone
-
2023-508960-31-00
5
2024-12-03
Metastatic HER2-positive breast cancer
-
2023-507776-42-00
5
2024-11-14
Non-small cell lung cancer
-
2023-506632-32-00
5
2024-10-28
Metastatic colorectal cancer
-
2024-511319-91-00
5
2024-10-23
Advanced non-small cell lung cancer with HER2 (ERBB2) mutation
-
2024-513087-26-00
5
2024-09-10
Metastatic Non-small Cell Lung Cancer